Sigma Healthcare has had a powerful run over the past few years, and a major shareholder has just sold a large block of stock. This puts a sharper focus on whether the current A$2.89 share price lines up with the cash the business is expected to generate. For anyone considering the stock today, the key issue is how that recent share price strength and ownership change stack up against an intrinsic value estimate built from its cash flows.
The issue now is whether Sigma Healthcare's recent share price of A$2.89 is appropriately supported by its Discounted Cash Flow (DCF) based intrinsic value estimate drawn from its cash flows.
If you want a broader starting point while you weigh Sigma Healthcare against its cash flows and insider selling, run the same questions across 5 resilient stocks with low risk scores.
The Discounted Cash Flow (DCF) model used here projects the cash Sigma Healthcare can return to shareholders and then brings those amounts back to today. On this view, the group generated about A$498.1 million of free cash flow over the last twelve months, with analyst and internal projections pointing to larger figures by 2030 and beyond. That path assumes cash generation grows rather than shrinks, then tapers into more modest expansion in the second stage of the model.
Those cash flow forecasts, once discounted, point to an estimated intrinsic value that sits meaningfully above the current A$2.89 share price. The recent A$250 million block sale by Chemist Warehouse co founder Sam Gance helps explain why some investors may hesitate to pay up for that cash flow profile, even with the model implying a gap between price and estimated worth. You can see how each input feeds into that intrinsic value estimate, and compare it with the current A$2.89 market price, in the full breakdown here. Find out what Sigma Healthcare could be worth using our Discounted Cash Flow (DCF) estimate.
Narratives on Sigma Healthcare sit on Simply Wall St's Community page and pick up where the cash flow puzzle leaves off. They spell out what would need to happen to growth, profitability and earnings for the stock to be worth substantially more or meaningfully less than it is today. Each scenario links its number to a clear view on how Sigma Healthcare's expansion, margins and risk profile might evolve, giving you a reference point you can revisit as fresh information comes through.
Bulls and bears looking at Sigma Healthcare are reading the same story but drawing very different conclusions on what that cash flow is worth.
Bull case: 8% undervalued
This view comes from the analyst consensus Narrative on Simply Wall St, which leans into scale, synergies and pharmacy demand.
"Ongoing consolidation of distribution centers, SAP integration across the merged group and the targeted A$100m per annum synergy program create scope for lower unit costs and better inventory efficiency…"
Discover why this Narrative puts Sigma Healthcare at 8% undervalued.
Bear case: 7% overvalued
The bearish analyst Narrative on Simply Wall St leans harder on working capital stretch and execution risk around expansion.
"Although expansion of owned and exclusive label products is approaching A$1b of sales and carries structurally higher margins, the larger inventory required, combined with a longer cash conversion cycle at 54 days, creates working capital pressure…"
Explore why this Narrative puts Sigma Healthcare at 7% overvalued.
Cash flows and scenarios only tell part of the story for Sigma Healthcare, because the real test is who is steering the ship, what they are rewarded for, and how that lines up with your interests. See who runs Sigma Healthcare and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com